Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 281 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 Ivosidenib with Chemotherapy New Option for Some People with AML May 13, 2022 Lucky 13-A Male Breast Cancer Story October 20, 2021 Dad With Cancer Escorts His Autistic Son To School, With The... August 13, 2019 Load more HOT NEWS Neighborhood Celebrates Teen’s Last Chemo Session With Socially-Distanced Parade NICE recommends pembrolizumab for 1,600 more people with breast cancer Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options... Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian...
